Kristie Zappas, PharmD

Innoviva Specialty Therapeutics, Inc.
Waltham, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 570 - Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)

  Wednesday, October 22, 2025
  11:18 AM - 11:30 AM US ET